Your browser doesn't support javascript.
loading
Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria.
Rubeiz, Christine J; Asero, Ricardo; Betschel, Stephen; Craig, Timothy; Grumach, Anete; Hide, Michihiro; Lang, David; Levin, Michael; Longhurst, Hilary; Magan, Eli; Maurer, Marcus; Saini, Romi; Sussman, Gordon; Toubi, Elias; Van, Dinh Nguyen; Zuberier, Torsten; Bernstein, Jonathan A.
Afiliación
  • Rubeiz CJ; Cincinnati Children's Hospital Medical Center, Division of Allergy and Immunology, Cincinnati, OH, USA.
  • Asero R; Ambulatorio di Allergologia, Clinica San Carlo, Pademo Dugnano, Italy.
  • Betschel S; Unity Health, St Michael's Hospital, University of Toronto, Ontario, Canada.
  • Craig T; Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA.
  • Grumach A; Centro Universitário Faculdade de Medicina ABC, Brazil.
  • Hide M; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Lang D; Cleveland Clinic Lerner College of Medicine, Department of Allergy and Clinical Immunology, Cleveland, OH, USA.
  • Levin M; University of Cape Town, South Africa.
  • Longhurst H; Department of Medicine, University of Auckland, Te Toka Tumai, New Zealand.
  • Magan E; Department of Immunology, Auckland City Hospital, Te Toka Tumai, New Zealand.
  • Maurer M; Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Israel.
  • Saini R; Charité and Fraunhofer, Berlin, Germany.
  • Sussman G; Johns Hopkins University School of Medicine, USA.
  • Toubi E; University of Ontario, Canada.
  • Van DN; University of Haifa, Israel.
  • Zuberier T; Vinmec Health Care System, China.
  • Bernstein JA; College of Health Sciences, Vin University, China.
World Allergy Organ J ; 17(1): 100858, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38235261
ABSTRACT

Background:

Chronic spontaneous urticaria (CSU) is a common condition treated by allergist/immunologists, but the only FDA-approved biologic medication, omalizumab, may be underutilized globally.

Objective:

This study was performed to determine the global prescription of omalizumab for treatment of CSU by allergists/immunologists.

Methods:

Anonymous questionnaire surveys were distributed online to World Allergy Organization (WAO) members worldwide. Categorical data were analyzed for descriptive analysis using one-way frequency tabulation in SAS 9.4.

Results:

There were 348 respondents (43 missing data); Average age 51 (range 28-90); M/F 48%/52%. 58% had > 15 years of clinical experience and 10% < 5; 42% worked in private clinics, 36% public hospitals, 24% academia, 18% private hospitals, and 4% in community practice. Eighty-two percent (82%) prescribed omalizumab for CSU patients and use of omalizumab was highest among young practitioners. The most significant barriers were cost (63%) and restricted formulary (24%). Drug safety (63%) and chances of adverse events (47%) were the most significant factors deciding treatment. Twenty-two percent (22%) reported 80-100% of CSU patients were complete responders to omalizumab; 34% preferred increasing frequency (q 2-weeks), and 18% preferred increasing dose (600 mg q 4-weeks) for partial or non-responders. UAS7, UCT, and CU-QoL were used to assess CSU by 55%, 29%, and 25% of respondents, respectively. Autoimmune thyroid disease (62%), thyroid abnormality (43%) and allergic rhinitis (35%) were the most frequent comorbidities reported.

Conclusions:

Most clinicians favored omalizumab over other potential treatments due to safety. Although younger clinicians were more likely to prescribe omalizumab, cost and formulary access were major barriers. Only 22% of respondents reported 80% or greater of their patients had complete response to omalizumab, indicating the need for novel CSU therapies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World Allergy Organ J Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World Allergy Organ J Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos